Related Experiment Video
Updated: Jun 22, 2026
Isolation of Functional Cardiac Immune Cells
Published on: December 5, 2011
Mast cells, peptides and cardioprotection - an unlikely marriage?
S K Walsh1, K A Kane, C L Wainwright
1Anu Research Centre, Department of Obstetrics & Gynaecology, University College Cork, Cork University Maternity Hospital, Cork, Ireland.
Insights
Mast cell degranulation can harm or protect heart tissue during ischemia. Pre-ischemia mast cell degranulation may offer cardioprotection, potentially explaining how various peptides protect the heart.
Area of Science:
- Cardiovascular Science
- Immunology
- Pharmacology
Background:
- Mast cells are traditionally viewed as detrimental in myocardial ischemia due to released inflammatory mediators.
- Emerging evidence suggests pre-emptive mast cell degranulation might be cardioprotective by depleting injurious substances.
- Various peptides (e.g., ET-1, adrenomedullin) show cardioprotection when administered before ischemia, with mechanisms often unclear.
Purpose of the Study:
- To review the dual role of mast cell degranulation in myocardial ischemia.
- To explore the potential common mechanism of peptide-induced cardioprotection via mast cell modulation.
Main Methods:
- Literature review consolidating evidence on mast cell degranulation and ischemia.
- Analysis of studies investigating peptide effects on mast cells and myocardial protection.
Main Results:
- Mast cell degranulation's impact on myocardial ischemia is time-dependent, being detrimental during acute ischemia but potentially protective if preceding it.
- Peptides known for cardioprotection may exert their effects by modulating mast cell degranulation or stabilization.
- Mast cell modulation presents a unifying hypothesis for the cardioprotective actions of diverse cardiovascular peptides.
Conclusions:
- Mast cell degranulation plays a context-dependent role in myocardial ischemia.
- Modulating mast cell activity represents a potential therapeutic strategy for cardioprotection.
- Understanding peptide-mast cell interactions may reveal novel pathways for treating ischemic heart conditions.
Abstract:
1 Mast cells have classically been regarded as the 'bad guys' in the setting of acute myocardial ischaemia, where their released contents are believed to contribute both to tissue injury and electrical disturbances resulting from ischaemia. Recent evidence suggests, however, that if mast cell degranulation occurs in advance of ischaemia onset, this may be cardioprotective by virtue of the depletion of mast cell contents that can no longer act as instruments of injury when the tissue becomes ischaemic. 2 Many peptides, such as ET-1, adrenomedullin, relaxin and atrial natriuretic peptide, have been demonstrated to be cardioprotective when given prior to the onset of myocardial ischaemia, although their physiological functions are varied and the mechanisms of their cardioprotective actions appear to be diverse and often ill defined. However, one common denominator that is emerging is the ability of these peptides to modulate mast cell degranulation, raising the possibility that peptide-induced mast cell degranulation or stabilization may hold the key to a common mechanism of their cardioprotection. 3 The aim of this review was to consolidate the evidence implying that mast cell degranulation could play both a detrimental and protective role in myocardial ischaemia, depending upon when it occurs, and that this may underlie the cardioprotective effects of a range of diverse peptides that exerts physiological effects within the cardiovascular system.
Related Concept Videos
01:38Inflammation
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:21Paracrine Signaling
00:42Cross-reactivity
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications